CY1110212T1 - Χαμηλης υγροσκοπικοτητας αριπιπραζολη ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της - Google Patents

Χαμηλης υγροσκοπικοτητας αριπιπραζολη ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της

Info

Publication number
CY1110212T1
CY1110212T1 CY20101100530T CY101100530T CY1110212T1 CY 1110212 T1 CY1110212 T1 CY 1110212T1 CY 20101100530 T CY20101100530 T CY 20101100530T CY 101100530 T CY101100530 T CY 101100530T CY 1110212 T1 CY1110212 T1 CY 1110212T1
Authority
CY
Cyprus
Prior art keywords
methods
aripiprazol
preparing
low humidity
medicinal products
Prior art date
Application number
CY20101100530T
Other languages
English (en)
Inventor
Takuji Bando
Satoshi Aoki
Junichi Kawasaki
Makoto Ishigami
Youichi Taniguchi
Tsuyoshi Yabuuchi
Kiyoshi Fujimoto
Yoshihiro Nishioka
Noriyuki Kobayashi
Tsutomu Fujimura
Masanori Takahashi
Kaoru Abe
Tomonori Nakagawa
Koichi Shinhama
Naoto Utsumi
Michiaki Tominaga
Yoshihiro Oi
Shohei Yamada
Kenji Tomikawa
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36049773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110212(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Priority claimed from EP08000357A external-priority patent/EP1927355B1/en
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1110212T1 publication Critical patent/CY1110212T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει χαμηλής υγροσκοπικότητας μορφές της αριπιπραζόλης και μεθόδους για την παρασκευή αυτών των μορφών, οι οποίες δεν θα μετασχηματιστούν σε ενυδρίτες ή δε θα χάσουν την αρχική τους διαλυτότητα ακόμα και όταν ένα φαρμακευτικό παρασκεύασμα που περιέχει τους άνυδρους κρυστάλλους αριπιπραζόλης αποθηκεύεται για μία μακρά περίοδο.
CY20101100530T 2001-09-25 2010-06-11 Χαμηλης υγροσκοπικοτητας αριπιπραζολη ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της CY1110212T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001290645 2001-09-25
JP2001348276 2001-11-14
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
EP08000357A EP1927355B1 (en) 2001-09-25 2002-09-25 Low hygroscopic aripiprazole (crystal F) drug substance and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
CY1110212T1 true CY1110212T1 (el) 2015-01-14

Family

ID=36049773

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20101100529T CY1110208T1 (el) 2001-09-25 2010-06-11 Χαμηλης υγροσκοπικοτητας αριπιπραζολη (κρυσταλλος d) ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της
CY20101100531T CY1110070T1 (el) 2001-09-25 2010-06-11 Χαμηλης υγροσκοπικοτητας αριπιπραζολη (κρυσταλλος e) ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της
CY20101100530T CY1110212T1 (el) 2001-09-25 2010-06-11 Χαμηλης υγροσκοπικοτητας αριπιπραζολη ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της
CY20101100614T CY1110244T1 (el) 2001-09-25 2010-07-05 Χαμηλης υγροσκοπικοτητας αριπιπραζολη ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20101100529T CY1110208T1 (el) 2001-09-25 2010-06-11 Χαμηλης υγροσκοπικοτητας αριπιπραζολη (κρυσταλλος d) ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της
CY20101100531T CY1110070T1 (el) 2001-09-25 2010-06-11 Χαμηλης υγροσκοπικοτητας αριπιπραζολη (κρυσταλλος e) ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20101100614T CY1110244T1 (el) 2001-09-25 2010-07-05 Χαμηλης υγροσκοπικοτητας αριπιπραζολη ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της

Country Status (21)

Country Link
EP (1) EP3081216A1 (el)
KR (2) KR100490222B1 (el)
CN (12) CN103755632B (el)
AR (3) AR073111A2 (el)
CA (1) CA2713466C (el)
CL (1) CL2010000405A1 (el)
CY (4) CY1110208T1 (el)
DK (1) DK1925308T3 (el)
ES (1) ES2596354T3 (el)
HK (14) HK1203059A1 (el)
IL (3) IL204707A (el)
LT (1) LT1925308T (el)
MY (1) MY138669A (el)
NO (1) NO337844B1 (el)
PE (1) PE20030445A1 (el)
PH (1) PH12014500782A1 (el)
PL (7) PL221521B1 (el)
PT (1) PT1925308T (el)
RU (1) RU2279429C2 (el)
SI (1) SI1927357T1 (el)
TW (2) TWI332839B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200602347B (en) * 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR102128883B1 (ko) * 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JP3638447B2 (ja) * 1998-09-10 2005-04-13 積水ハウス株式会社 笠木取付金具および笠木取付構造
GB9930061D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Quinolone compounds for use in treating viral infections
NZ519981A (en) * 2000-01-20 2005-02-25 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
WO2003030868A1 (en) * 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
JP2002193915A (ja) * 2000-12-28 2002-07-10 Otsuka Pharmaceut Co Ltd ベンゼンスルフォナート化合物

Also Published As

Publication number Publication date
TWI318572B (en) 2009-12-21
CN103751118A (zh) 2014-04-30
IL234770A0 (en) 2014-11-30
PL393607A1 (pl) 2011-03-14
HK1196128A1 (zh) 2014-12-05
CN103751119A (zh) 2014-04-30
CN103755632A (zh) 2014-04-30
IL225902A0 (en) 2013-06-27
CN103288727B (zh) 2016-04-27
NO337844B1 (no) 2016-06-27
PL230869B1 (pl) 2018-12-31
HK1136961A1 (en) 2010-07-16
HK1092808A1 (en) 2007-02-16
TWI332839B (en) 2010-11-11
CN103755632B (zh) 2016-06-29
CN104945321A (zh) 2015-09-30
PT1925308T (pt) 2016-10-24
CA2713466A1 (en) 2003-04-03
CY1110070T1 (el) 2015-01-14
PL393603A1 (pl) 2011-04-26
KR20030060871A (ko) 2003-07-16
LT1925308T (lt) 2016-11-10
PL393596A1 (pl) 2011-04-26
DK1925308T3 (en) 2016-12-12
PL221536B1 (pl) 2016-04-29
NO20141193L (no) 2003-01-17
KR100530731B1 (ko) 2005-11-23
CA2713466C (en) 2012-01-03
PL219565B1 (pl) 2015-05-29
IL204707A (en) 2016-06-30
HK1136960A1 (en) 2010-07-16
MY138669A (en) 2009-07-31
IL204707A0 (en) 2010-11-30
EP3081216A1 (en) 2016-10-19
CN105267151A (zh) 2016-01-27
CN103288727A (zh) 2013-09-11
PE20030445A1 (es) 2003-07-26
HK1187048A1 (zh) 2014-03-28
HK1203059A1 (en) 2015-10-16
HK1210468A1 (en) 2016-04-22
HK1129889A1 (en) 2009-12-11
CN103191118A (zh) 2013-07-10
AR077635A2 (es) 2011-09-14
CY1110244T1 (el) 2015-01-14
PL221521B1 (pl) 2016-04-29
RU2004126636A (ru) 2006-02-10
KR20040053372A (ko) 2004-06-23
HK1136959A1 (en) 2010-07-16
HK1223043A1 (zh) 2017-07-21
PL393601A1 (pl) 2011-04-26
HK1215397A1 (zh) 2016-08-26
PL417178A1 (pl) 2016-07-04
HK1136958A1 (en) 2010-07-16
CY1110208T1 (el) 2015-01-14
CN105832677A (zh) 2016-08-10
TW200942238A (en) 2009-10-16
AR073111A2 (es) 2010-10-13
AR087544A2 (es) 2014-04-03
CL2010000405A1 (es) 2010-10-15
CN102579446A (zh) 2012-07-18
PL219564B1 (pl) 2015-05-29
ES2596354T3 (es) 2017-01-09
CN104306374A (zh) 2015-01-28
SI1927357T1 (sl) 2010-09-30
CN103751093A (zh) 2014-04-30
HK1203060A1 (en) 2015-10-16
PH12014500782A1 (en) 2018-09-10
HK1129891A1 (en) 2009-12-11
CN104306337A (zh) 2015-01-28
PL393608A1 (pl) 2011-03-14
RU2279429C2 (ru) 2006-07-10
PL393598A1 (pl) 2011-04-26
KR100490222B1 (ko) 2005-05-18

Similar Documents

Publication Publication Date Title
CY1118195T1 (el) Φαρμακευτικο στερεο στοματικο παρασκευασμα αριπιπραζολης και μεθοδοι για την παρασκευη αυτου
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1114728T1 (el) Φαρμακοτεχνικη μορφη εισπνοης περιλαμβανουσα παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
CY1105247T1 (el) Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης
CY1108101T1 (el) Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη
CY1108547T1 (el) Αναλογα σωματοστατινης
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
NO333265B3 (no) Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne.
CY1113890T1 (el) Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων
CY1108378T1 (el) 4-υποκατεστημενα παραγωγα 1-αμινοκυκλοεξανιου για την χρησιμοποιηση σαν προσδεματα υποδοχεα orl1 ή οπιακου υποδοχεα mu
DE60007095T2 (de) Calanolide zur hemmung von btk
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
ATE369857T1 (de) Methode zur stabilisierung von benzimidazol- verbindungen
CY1107230T1 (el) Υποκατεστημενες ενωσεις 1-φαιναιθυλοπιπεριδινης, οι οποιες μεταξυ αλλων χρησιμοποιουνται σαν αναλγητικα
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
CY1110212T1 (el) Χαμηλης υγροσκοπικοτητας αριπιπραζολη ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
SE0202693D0 (sv) Compounds
ATE391489T1 (de) Haarbehandlungszusammensetzungen
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
CY1105363T1 (el) Ν,ν΄-διυποκατεστημενες ενωσεις πιπepαζινης και η χρηση τους σαν αναλγητικα μεσα
TW200510379A (en) 1, 4-disubstituted piperidine compounds, their preparation and use as medicaments